140 related articles for article (PubMed ID: 12427285)
21. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells.
Yurkovetsky ZR; Shurin GV; Barry DA; Schuh AC; Shurin MR; Robbins PD
J Gene Med; 2006 Feb; 8(2):129-37. PubMed ID: 16288496
[TBL] [Abstract][Full Text] [Related]
22. Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease.
Gruss HJ; Duyster J; Herrmann F
Ann Oncol; 1996; 7 Suppl 4():19-26. PubMed ID: 8836404
[TBL] [Abstract][Full Text] [Related]
23. TNF-alpha, not CD154 (CD40L), plays a major role in SEB-dependent, CD4(+) T cell-induced endothelial cell activation in vitro.
Baum D; Yaron R; Yellin MJ
Cell Immunol; 1998 Nov; 190(1):12-22. PubMed ID: 9826442
[TBL] [Abstract][Full Text] [Related]
24. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo.
Sin JI; Kim JJ; Zhang D; Weiner DB
Hum Gene Ther; 2001 Jun; 12(9):1091-102. PubMed ID: 11399230
[TBL] [Abstract][Full Text] [Related]
25. Chronic immune activation in HIV-1 infection contributes to reduced interferon alpha production via enhanced CD40:CD40 ligand interaction.
Donhauser N; Pritschet K; Helm M; Harrer T; Schuster P; Ries M; Bischof G; Vollmer J; Smola S; Schmidt B;
PLoS One; 2012; 7(3):e33925. PubMed ID: 22470494
[TBL] [Abstract][Full Text] [Related]
26. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production.
Liu Z; Colpaert S; D'Haens GR; Kasran A; de Boer M; Rutgeerts P; Geboes K; Ceuppens JL
J Immunol; 1999 Oct; 163(7):4049-57. PubMed ID: 10491009
[TBL] [Abstract][Full Text] [Related]
27. A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system.
Tomura M; Yu WG; Ahn HJ; Yamashita M; Yang YF; Ono S; Hamaoka T; Kawano T; Taniguchi M; Koezuka Y; Fujiwara H
J Immunol; 1999 Jul; 163(1):93-101. PubMed ID: 10384104
[TBL] [Abstract][Full Text] [Related]
28. Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment.
Imbeault M; Ouellet M; Giguère K; Bertin J; Bélanger D; Martin G; Tremblay MJ
J Virol; 2011 Mar; 85(5):2189-200. PubMed ID: 21177803
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of CD40 ligand/trimer stimulation on the ability of dendritic cells to replicate and transmit HIV infection: evidence for CC-chemokine-dependent and -independent mechanisms.
McDyer JF; Dybul M; Goletz TJ; Kinter AL; Thomas EK; Berzofsky JA; Fauci AS; Seder RA
J Immunol; 1999 Mar; 162(6):3711-7. PubMed ID: 10092834
[TBL] [Abstract][Full Text] [Related]
30. Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction.
Klaus SJ; Pinchuk LM; Ochs HD; Law CL; Fanslow WC; Armitage RJ; Clark EA
J Immunol; 1994 Jun; 152(12):5643-52. PubMed ID: 7515910
[TBL] [Abstract][Full Text] [Related]
31. Interferon-gamma and tumour necrosis factor-alpha production by CD4+ T and CD8+ T lymphocytes in AIDS patients with tuberculosis.
de Castro Cunha RM; Kallas EG; Rodrigues DS; Nascimento Burattini M; Salomao R
Clin Exp Immunol; 2005 Jun; 140(3):491-7. PubMed ID: 15932510
[TBL] [Abstract][Full Text] [Related]
32. CD40 ligand is pivotal to efficient control of virus replication in mice infected with lymphocytic choriomeningitis virus.
Thomsen AR; Nansen A; Christensen JP; Andreasen SO; Marker O
J Immunol; 1998 Nov; 161(9):4583-90. PubMed ID: 9794385
[TBL] [Abstract][Full Text] [Related]
33. The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells.
Merz C; Sykora J; Marschall V; Richards DM; Heinonen K; Redondo Müller M; Thiemann M; Schnyder T; Fricke H; Hill O; Gieffers C
J Immunother; 2018; 41(9):385-398. PubMed ID: 30273198
[TBL] [Abstract][Full Text] [Related]
34. Early reduction of the over-expression of CD40L, OX40 and Fas on T cells in HIV-1 infection during triple anti-retroviral therapy: possible implications for lymphocyte traffic and functional recovery.
Sousa AE; Chaves AF; Doroana M; Antunes F; Victorino RM
Clin Exp Immunol; 1999 May; 116(2):307-15. PubMed ID: 10337023
[TBL] [Abstract][Full Text] [Related]
35. Evidence for a continued requirement for CD40/CD40 ligand (CD154) interactions in the progression of LP-BM5 retrovirus-induced murine AIDS.
Green KA; Noelle RJ; Green WR
Virology; 1998 Feb; 241(2):260-8. PubMed ID: 9499800
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the CD40L/Oncostatin M/Oncostatin M receptor axis as an antiviral and immunostimulatory system disrupted in chronic HCV infection.
Larrea E; Echeverria I; Riezu-Boj JI; Aldabe R; Guembe L; Sola I; Civeira MP; Sarobe P; Prieto J
J Hepatol; 2014 Mar; 60(3):482-9. PubMed ID: 24418171
[TBL] [Abstract][Full Text] [Related]
37. B cells regulate CD40 ligand-induced IL-12 production in antigen-presenting cells (APC) during T cell/APC interactions.
Maruo S; Oh-hora M; Ahn HJ; Ono S; Wysocka M; Kaneko Y; Yagita H; Okumura K; Kikutani H; Kishimoto T; Kobayashi M; Hamaoka T; Trinchieri G; Fujiwara H
J Immunol; 1997 Jan; 158(1):120-6. PubMed ID: 8977182
[TBL] [Abstract][Full Text] [Related]
38. CD40L, CD28, and CTLA-4 expression on CD4+ T cells in kidney graft recipients: a relationship with post-transplantation clinical course.
Kosmaczewska A; Magott-Procelewska M; Frydecka I; Ciszak L; Bocko D; Szteblich A; Kusnierczyk P; Patrzalek D; Szyber P; Klinger M
Transpl Immunol; 2006 Jun; 16(1):32-40. PubMed ID: 16701174
[TBL] [Abstract][Full Text] [Related]
39. Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bcl-2 expression and consequences for AIDS pathogenesis.
Ledru E; Lecoeur H; Garcia S; Debord T; Gougeon ML
J Immunol; 1998 Apr; 160(7):3194-206. PubMed ID: 9531275
[TBL] [Abstract][Full Text] [Related]
40. The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy.
Frankish J; Mukherjee D; Romano E; Billian-Frey K; Schröder M; Heinonen K; Merz C; Redondo Müller M; Gieffers C; Hill O; Thiemann M; Honeychurch J; Illidge T; Sykora J
Front Immunol; 2023; 14():1160116. PubMed ID: 37304285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
